Discoidin domain receptor tyrosine kinases (DDRs) are a class of receptor tyrosine kinases (RTKs), and their dysregulation is associated with multiple diseases (including cancer, chronic inflammatory conditions, and fibrosis). The DDR family members (DDR1a-e and DDR2) are widely expressed, with predominant expression of DDR1 in epithelial cells and DDR2 in mesenchymal cells. Structurally, DDRs consist of three regions (an extracellular ligand binding domain, a transmembrane domain, and an intracellular region containing a kinase domain), with their kinase activity induced by receptor-specific ligand binding. Collagen binding to DDRs stimulates DDR phosphorylation activating kinase activity, signaling to MAPK, integrin, TGF-β, insulin receptor, and Notch signaling pathways. Abnormal DDR expression is detected in a range of solid tumors (including breast, ovarian, cervical liver, gastric, colorectal, lung, and brain). During tumorigenesis, abnormal activation of DDRs leads to invasion and metastasis, via dysregulation of cell adhesion, migration, proliferation, secretion of cytokines, and extracellular matrix remodeling. Differential expression or mutation of DDRs correlates with pathological classification, clinical characteristics, treatment response, and prognosis. Here, we discuss the discovery, structural characteristics, organizational distribution, and DDR-dependent signaling. Importantly, we highlight the key role of DDRs in the development and progression of breast and ovarian cancer.
Centrosome amplification (CA), a prominent feature of human cancers linked to genomic instability and tumourigenesis in vivo, is observed as early as pre-malignant metaplasia, increasing with progression from dysplasia to neoplasia. However, the mechanistic contributions of CA to tumourigenesis are not fully understood.Using non-tumourigenic breast cells (MCF10A), we demonstrate that induction of CA (by CDK1 inhibition or PLK4 overexpression) increased both the migration and invasion of non-tumourigenic cells. Mechanistically, we found small GTPase Rap-1 was activated upon CA induction. Rap-1 inhibition (using GGTI-298) blocked CA-induced migration, invasion and ECM attachment, demonstrating the role of Rap-1 in CA induced tumourigenesis.Induction of CA in a long-term cell culture system disrupted epithelial cell-cell junction integrity, via dysregulation of expression and subcellular localisation of cell junction proteins (ZO-1, Occludin, JAM-A & β-catenin). Physically, CA inhibited apical junctional complex formation, visualised by transmission electron microscopy. Furthermore, CA induction in non-tumourigenic cells elevated β-integrin 3 expression, potentially mediating increased cell attachment to the extracellular matrix (ECM) induced by CA. Simultaneously, CA induced elevated expression of matrix metalloprotease MMP1 and MMP13 facilitating ECM degradation and cell invasion.In vivo validation in a Chicken Embryo xenograft model, showed CA+ MCF10A cells invaded into the chicken mesodermal layer, characterised by inflammatory cell infiltration and a marked focal reaction between chorioallantoic membrane and cell graft. This reaction was inhibited by pre-treatment of CA+ MCF10A cells with Rap-1 inhibitor GGTI-298. Inhibition of CA in metastatic breast cancer cells with high levels of endogenous CA (triple negative cell line MDA-MB-231), using PLK4 inhibitor Centrinone B, abrogated their metastatic capacity in vitro.Here, we demonstrated CA induction in normal cells confers early tumourigenic changes which promote tumour progression, mediated by ECM disruption, altered cell-cell contacts, and Rap-1-dependent signaling. These insights fundamentally demonstrate the mechanism of how CA induces tumourigenesis in normal cells, alone and without requiring additional pre-tumourigenic alterations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.